SecBot SecBot
SECBOTREPLAY Home › Report › ACAD

ACAD · Acadia Pharmaceuticals Q1 2026 earnings missed consensus sharply with…

ACADIA PHARMACEUTICALS INC · 8-K filed May 6, 2026 at 16:50 ET

At the news

BEARISHIMPACT 6/10

8-K filed May 6, 2026 at 16:50 ET

Acadia Pharmaceuticals Q1 2026 earnings missed consensus sharply with EPS of $0.02 (vs $0.08 est) and revenue of $268M (vs $280.3M est). Revenue grew 10% YoY, but EPS fell 82% YoY due to a 36% surge in SG&A expenses. Full-year 2026 guidance was reaffirmed, providing some stability.

  • Q1 2026 GAAP revenue $268M, up 10% YoY from $244M
  • Q1 2026 GAAP diluted EPS $0.02, down 82% from $0.11 YoY
  • SG&A expense $171M, up 36% from $126M YoY, driving operating loss
  • DAYBUE net sales $101M (+20% YoY), NUPLAZID $167M (+5% GAAP, +6% adjusted)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access